Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Slides:

Advertisements

Similar presentations

Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.

Advertisements

Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

Lipid Disorders and Management in Diabetes

DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.

DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

First time a CETP inhibitor shows reduction of serious CV events

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

New Insights on PPAR Agonists For Cardiovascular Disease

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Back to the Basics of Dyslipidemia

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cholesteryl Ester Transfer Protein Inhibitors

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Patient 1: 53-Year-Old Man With CVD Risk Factors

Select Topics in Cardiovascular Medicine

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Statins and the Elderly Patient

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Shedding Light on HDL: Myths and Controversies

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

What Do We Know About LDL-C?

These slides highlight a cardiology grand rounds and cardiology research rounds presented by William James Howard, MD at St. Michael’s Hospital, in Toronto,

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

TNT Study: Baseline Characteristics of the Patients

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

CV Risk Doesn't End in the Cath Lab

Personalizing Statin Therapy in Patients With HIV

PCSK9 Inhibitors and Cardiovascular Outcomes

Cardiometabolic Risk: What Can the PPAR-Alpha Agonists Teach Us?

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

Lipid Clinic Challenge

CV Risk Doesn't End in the Cath Lab

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

Préparation ESC Septembre

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Updates on Dyslipidemia

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Section 6: Update on lipid treatment guidelines

Shared-Decision Making in Dyslipidemia

Presentation transcript:

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

Guideline Recommendations

Approximate Dose Equivalency of Statin LDL-C Efficacy

NEPTUNE II Trial

Residual CV Risk

Intensive Statin Therapy: Residual CV Risk

Combination Therapy

Statin + Fibrates

VA-HIT: Gemfibrozil Prevents Secondary CVD Events

ACCORD Lipid: Hazard Ratios for the Primary Outcome

Comparison of ACCORD Subgroup Results With Those From Prior Fibrate Studies

Statin + Niacin

AIM-HIGH: End Point at 36-month Follow-Up

HPS2-THRIVE: Effects of Niacin/Laropiprant on Lipids

HPS2-THRIVE: Major Vascular Events

Statin + Ezetimibe

Statin and Ezetimibe Trials

Statin and Ezetimibe

ENHANCE Simvastatin/Ezetimibe in Familial Hypercholesterolemia

ENHANCE Simvastatin/Ezetimibe in High Cholesterol Absorbers and Synthesizers

ENHANCE Change in Intima Media Thickness of Carotid Artery

EZ-Switch Study: Ezetimibe Added to Atorvastatin vs Atorvastatin Up-Titration or Switching to Rosuvastatin

LDL-C: Percentage Change From Baseline at End of Phase 1/2

ARBITER 6-HALTS Trial

Statin + Bile Acid Sequestrants

Comparison of CETP Inhibitors

DAL-OUTCOMES: 3 Years

Abbreviations

Abbreviations (cont)

Abbreviations (cont)